Detalhe da pesquisa
1.
Antitumor activity of ipilimumab or BRAF ± MEK inhibition after pembrolizumab treatment in patients with advanced melanoma: analysis from KEYNOTE-006.
Ann Oncol
; 33(2): 204-215, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34710571
2.
Changes in serum interleukin-8 (IL-8) levels reflect and predict response to anti-PD-1 treatment in melanoma and non-small-cell lung cancer patients.
Ann Oncol
; 28(8): 1988-1995, 2017 Aug 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28595336
3.
Revisiting anti-CTLA-4 antibodies in combination with PD-1 blockade for cancer immunotherapy.
Ann Oncol
; 32(3): 295-297, 2021 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-33307201
4.
Pilot study of interleukin-2 and lymphokine-activated killer cells combined with immunomodulatory doses of chemotherapy and sequenced with interferon alfa-2a in patients with metastatic melanoma and renal cell carcinoma.
J Natl Cancer Inst
; 84(12): 929-37, 1992 Jun 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-1629914
5.
Phase I study of high-dose continuous-infusion recombinant interleukin-2 and autologous lymphokine-activated killer cells in patients with metastatic or unresectable malignant melanoma and renal cell carcinoma.
J Natl Cancer Inst
; 82(17): 1397-402, 1990 Sep 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-2388289
6.
Phase II trial of interleukin 1 alpha and indomethacin in treatment of metastatic melanoma.
J Natl Cancer Inst
; 88(1): 44-9, 1996 Jan 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-8847725
7.
Anti-CD3 monoclonal antibody treatment of patients with CD3-negative tumors: a phase IA/B study.
Cancer Res
; 52(9): 2394-401, 1992 May 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-1533172
8.
Phase I and immunomodulatory study of a muramyl peptide, muramyl tripeptide phosphatidylethanolamine.
Cancer Res
; 50(10): 2979-86, 1990 May 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-1692252
9.
Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy.
J Clin Oncol
; 13(3): 688-96, 1995 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-7884429
10.
A phase II study of high-dose continuous infusion interleukin-2 with lymphokine-activated killer cells in patients with metastatic melanoma.
J Clin Oncol
; 9(4): 641-8, 1991 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-2066760
11.
Randomized phase III trial of treatment with high-dose interleukin-2 either alone or in combination with interferon alfa-2a in patients with advanced melanoma.
J Clin Oncol
; 11(10): 1969-77, 1993 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-8410122
12.
Phase IB clinical trial of anti-CD3 followed by high-dose bolus interleukin-2 in patients with metastatic melanoma and advanced renal cell carcinoma: clinical and immunologic effects.
J Clin Oncol
; 11(8): 1496-505, 1993 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-8336188
13.
Dose-related immunologic effects of levamisole in patients with cancer.
J Clin Oncol
; 11(1): 125-35, 1993 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-8418223
14.
A randomized phase II trial of continuous infusion interleukin-2 or bolus injection interleukin-2 plus lymphokine-activated killer cells for advanced renal cell carcinoma.
J Clin Oncol
; 10(2): 275-81, 1992 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-1732429
15.
High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993.
J Clin Oncol
; 17(7): 2105-16, 1999 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-10561265
16.
Therapy of renal cell carcinoma with interleukin-2 and lymphokine-activated killer cells: phase II experience with a hybrid bolus and continuous infusion interleukin-2 regimen.
J Clin Oncol
; 8(10): 1630-6, 1990 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-2213100
17.
Interleukin-2 therapy in patients with metastatic malignant melanoma: a phase II study.
J Clin Oncol
; 8(10): 1650-6, 1990 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-2213101
18.
Metastatic malignant melanoma treated with combined bolus and continuous infusion interleukin-2 and lymphokine-activated killer cells.
J Clin Oncol
; 8(7): 1138-47, 1990 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-2358835
19.
Phase I trial of anti-CD3-stimulated CD4+ T cells, infusional interleukin-2, and cyclophosphamide in patients with advanced cancer.
J Clin Oncol
; 16(8): 2752-60, 1998 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-9704728
20.
Phase I study of subcutaneously administered interleukin-2 in combination with interferon alfa-2a in patients with advanced cancer.
J Clin Oncol
; 14(8): 2234-41, 1996 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-8708712